About Admin

David experienced an adverse event to the the fluoroquinolone Levaquin in 2007 at age 46. Prior to, he was a healthy law enforcement official. Now, disabled with drug induced mitochondrial disease/dysfunction, he is an FQ patient safety advocate, citizen scientist, FQ researcher, author, and commentator. He has contributed to case studies and published academic papers on the FQ’s in the BMJ, European Journal of Medicine, The Journal of Community and Supportive Oncology, Oxford Academic Clinical infectious Diseases, and contributed data to many more outlets.

FDA Changes Fluoroquinolone Label But Denies Citizen Petition on Mitochondrial Toxicity

On Thursday May 12, 2016 the FDA contacted those who have been pursuing label changes for the Fluoroquinolones and issued a public statement that the FDA is requiring label changes for antibacterial drugs called fluoroquinolones

Dr. Bennett Publishes Paper on Fluoroquinolone Neuropsychiatric & Mitochondrial Toxicity

Dr. Charles Bennett has been able to successfully publish a paper titled "Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network."

The Voices Heard Round The World – The November 5th FDA Meeting

On Nov. 5th, the true stars of our community took to the podium at the FDA to tell their personal stories. I, along with countless others, were humbled and honored. This meeting represented a huge step in the progress we are making to gain complete recognition of the travesty that the fluoroquinolone class of pharmaceuticals has wrought upon society, to achieve justice for those that have been damaged by these drugs, and to prevent future unnecessary pain and suffering not only for this generation, but for generations to come.

Fluoroquinolone Academic Research Update – Dr. Mark Noble, Part #1

A interesting two part series covering our five year research relationship with Dr. Noble, U of R; He has assisted us with a submission for the upcoming FDA Meeting, asked us to collect data for his research, and in part 2 reveals troubling findings about Levaquin.

FDA To Hold Upcoming Meeting on Fluoroquinolones

We believe that the attention given the Fluoroquinolones through the combined media stories, past rallies, citizen petitions, in addition to community members meeting directly with FDA officials, provided some of the impetus, in part, for the scrutiny of the Fluoroquinolones being prescribed for these common health conditions.